URBAN, MARIA LETIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.427
EU - Europa 4.033
AS - Asia 3.521
SA - Sud America 653
Continente sconosciuto - Info sul continente non disponibili 147
AF - Africa 112
OC - Oceania 37
Totale 13.930
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.294
RU - Federazione Russa 1.435
IT - Italia 1.219
CN - Cina 889
SG - Singapore 887
HK - Hong Kong 523
BR - Brasile 513
VN - Vietnam 353
KR - Corea 293
IE - Irlanda 273
PL - Polonia 207
SE - Svezia 207
FR - Francia 170
DE - Germania 130
BD - Bangladesh 117
IN - India 110
FI - Finlandia 103
CA - Canada 76
GB - Regno Unito 69
AR - Argentina 63
IQ - Iraq 57
ID - Indonesia 56
JP - Giappone 52
CH - Svizzera 49
NL - Olanda 44
ES - Italia 41
JO - Giordania 41
AU - Australia 34
MX - Messico 28
ZA - Sudafrica 21
UA - Ucraina 20
CI - Costa d'Avorio 18
EC - Ecuador 17
IR - Iran 17
TR - Turchia 17
PY - Paraguay 16
UZ - Uzbekistan 15
BE - Belgio 13
NG - Nigeria 13
PK - Pakistan 13
AT - Austria 12
EG - Egitto 12
CO - Colombia 11
MY - Malesia 11
PT - Portogallo 11
CL - Cile 10
KE - Kenya 10
SA - Arabia Saudita 9
VE - Venezuela 9
MA - Marocco 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
BJ - Benin 7
TH - Thailandia 7
TW - Taiwan 7
AM - Armenia 6
DZ - Algeria 6
JM - Giamaica 6
CR - Costa Rica 5
GR - Grecia 5
GT - Guatemala 5
HN - Honduras 5
HU - Ungheria 5
LY - Libia 5
PE - Perù 5
TN - Tunisia 5
UY - Uruguay 5
AZ - Azerbaigian 4
NP - Nepal 4
BO - Bolivia 3
NZ - Nuova Zelanda 3
SN - Senegal 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
KH - Cambogia 2
LB - Libano 2
MK - Macedonia 2
OM - Oman 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
BF - Burkina Faso 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
GD - Grenada 1
GF - Guiana Francese 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
Totale 13.774
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.327
Ashburn 780
Singapore 647
Hong Kong 457
San Jose 306
Seoul 293
Dublin 274
Hefei 255
Fairfield 233
Milan 215
Warsaw 203
Chandler 192
Beijing 171
Ho Chi Minh City 130
Florence 114
Buffalo 106
Los Angeles 102
Seattle 102
Rome 101
Woodbridge 100
Houston 97
Moscow 97
Council Bluffs 93
Hanoi 84
Lawrence 80
New York 79
Lauterbourg 77
Altamura 76
Cambridge 74
The Dalles 72
Wilmington 71
Ann Arbor 68
Helsinki 65
Mumbai 61
Dallas 59
Boston 56
Paris 56
Princeton 54
Munich 42
Bern 41
São Paulo 41
Baghdad 37
Kent 35
Phoenix 34
Melbourne 33
Tokyo 33
Shanghai 29
Jakarta 28
Chicago 27
Boardman 26
San Diego 25
Guangzhou 22
Naples 22
Turin 22
Figino 21
Frankfurt am Main 21
Montreal 21
Orem 21
Bengaluru 19
Bologna 19
Lappeenranta 19
Abidjan 18
Medford 18
Rio de Janeiro 16
Turku 16
London 15
Da Nang 14
Haiphong 14
Tashkent 14
Brooklyn 13
Brussels 13
Cagliari 12
Palermo 12
Bari 11
Biên Hòa 11
Falls Church 11
Toronto 11
Venice 11
Abuja 10
Atlanta 10
Belo Horizonte 10
Chennai 10
Genoa 10
Monza 10
Redondo Beach 10
San Francisco 10
Vienna 10
Brasília 9
Catania 9
Johannesburg 9
Mexico City 9
Arezzo 8
Dong Ket 8
Düsseldorf 8
Fossalunga 8
Miano 8
Norwalk 8
Nuremberg 8
Parma 8
Pescara 8
Totale 8.493
Salva come PNG Salva come JPEG
Nome #
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 309
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 264
Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre 263
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 256
IgG4-related disease and other fibro-inflammatory conditions 246
Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study 238
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 233
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature 227
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 217
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 203
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 202
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome 201
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 200
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 200
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 197
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 194
Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis 193
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 191
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 190
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial 187
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS 187
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 185
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 184
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 184
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 181
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 181
ModulAtion of gut Microbiota through nutritional interventions in Behçet's syndrome pAtients: the MAMBA Study 181
Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis 177
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 176
Significance of PR3-ANCA Positivity in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 176
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 175
Neutrophil-mediated mechanisms of damage and in vitro protective effect of colchicine in non-vascular Behçet's syndrome 175
Optical coherence tomography angiography findings in patients affected by giant cell arteritis, with and without ocular involvement: a pilot study 174
POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME 170
298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS 169
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 168
Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients 168
The impact of environmental factors on aetiopathogenesis and clinical manifestations of Behçet's syndrome 166
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 166
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 166
Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis 164
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 163
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study 162
Slowly progressive ANCA-associated renal vasculitis. Clinico-pathological characterisation and outcome 158
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis 155
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 154
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 154
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 149
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 149
Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis 149
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 148
The management of transitional care of patients affected by phenylketonuria in Italy: Review and expert opinion 145
Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature 143
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 143
Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases 143
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? 142
Rituximab therapy for chronic periaortitis 142
SIRT1 and thrombosis 142
Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation 141
Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome 141
SARS-CoV-2 infection among patients with systemic autoimmune diseases 136
Pathophysiology of IgG4-related disease: A T follicular helper cells disease? 135
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study 131
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 131
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 129
Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach 124
Towards needed improvements in inherited metabolic medicine in adulthood: The SIMMESN adult metabolic working group and MetabERN Joint Position Statement 120
Pharmacological interventions for the prevention of fetal growth restriction: a systematic review and network meta-analysis 120
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 119
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study 118
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 116
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis 113
Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis 111
Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives 110
Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case–control study 109
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 109
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 105
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases 105
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases 104
Editorial: New insights into pathophysiology and management of pregnancy in systemic autoimmune diseases: Toward new therapeutic approaches 103
Systemic Fibroinflammatory Disorders - Diffuse (Thoraco-Abdominal) Periaortitis 97
Treatment of idiopathic retroperitoneal fibrosis 90
Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study 86
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 81
Fibrosis - A Common Pathway to Organ Injury and Failure 74
Fc gamma-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 70
Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European Cohort 60
Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study 43
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0) 38
Recombinant hf-SCIg in inflammatory myositis: refining patient selection and outcome assessment. Author’s reply 19
Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial 17
Totale 13.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.936
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.936
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022479 0 0 85 19 15 56 14 42 29 20 87 112
2022/20231.179 90 255 72 53 50 203 170 68 106 12 41 59
2023/2024619 13 39 74 40 48 78 35 113 20 80 38 41
2024/20254.341 147 424 240 662 1.067 548 155 287 181 174 191 265
2025/20265.766 608 715 670 695 487 179 572 277 322 334 200 707
2026/2027571 227 145 199 0 0 0 0 0 0 0 0 0
Totale 13.930